Search Results - "Ogino, Atsuko"

Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors by Kosaka, Takayuki, Tanizaki, Junko, Paranal, Raymond M, Endoh, Hideki, Lydon, Christine, Capelletti, Marzia, Repellin, Claire E, Choi, Jihyun, Ogino, Atsuko, Calles, Antonio, Ercan, Dalia, Redig, Amanda J, Bahcall, Magda, Oxnard, Geoffrey R, Eck, Michael J, Jänne, Pasi A

“…Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20. Non-small cell lung cancer (NSCLC) patients with tumors harboring these…”
Get full text

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer by Tricker, Erin M, Xu, Chunxiao, Uddin, Sharmeen, Capelletti, Marzia, Ercan, Dalia, Ogino, Atsuko, Pratilas, Christine A, Rosen, Neal, Gray, Nathanael S, Wong, Kwok-Kin, Jänne, Pasi A

“…Irreversible pyrimidine-based EGFR inhibitors, including WZ4002, selectively inhibit both EGFR-activating and EGFR inhibitor-resistant T790M mutations more…”
Get more information

A Novel ALK Secondary Mutation and EGFR Signaling Cause Resistance to ALK Kinase Inhibitors by SASAKI, Takaaki, KOIVUNEN, Jussi, CAPELLETTI, Marzia, SHIMAMURA, Takeshi, ERCAN, Dalia, STUMPFOVA, Magda, YUN XIAO, WEREMOWICZ, Stanislawa, BUTANEY, Mohit, HEON, Stephanie, WILNER, Keith, CHRISTENSEN, James G, OGINO, Atsuko, ECK, Michel J, WONG, Kwok-Kin, LINDEMAN, Neal, GRAY, Nathanael S, RODIG, Scott J, JÄNNE, Pasi A, YANAGITA, Masahiko, NIKIFOROW, Sarah, ZHENG, Wei, LATHAN, Christopher, PAUL MARCOUX, J, JINYAN DU, OKUDA, Katsuhiro

“…Anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKI), including crizotinib, are effective treatments in preclinical models and in cancer patients…”
Get full text

Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non-small cell lung cancer cell line by OGINO, Atsuko, KITAO, Hiroyuki, HIRANO, Seiki, UCHIDA, Akiko, ISHIAI, Masamichi, KOZUKI, Toshiyuki, TAKIGAWA, Nagio, TAKATA, Minoru, KIURA, Katsuyuki, TANIMOTO, Mitsune

“…The epidermal growth factor receptor (EGFR)-specific tyrosine kinase inhibitor gefitinib may provide dramatic clinical responses in some patients with…”
Get full text

An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer by To, Ciric, Beyett, Tyler S, Jang, Jaebong, Feng, William W, Bahcall, Magda, Haikala, Heidi M, Shin, Bo H, Heppner, David E, Rana, Jaimin K, Leeper, Brittaney A, Soroko, Kara M, Poitras, Michael J, Gokhale, Prafulla C, Kobayashi, Yoshihisa, Wahid, Kamal, Kurppa, Kari J, Gero, Thomas W, Cameron, Michael D, Ogino, Atsuko, Mushajiang, Mierzhati, Xu, Chunxiao, Zhang, Yanxi, Scott, David A, Eck, Michael J, Gray, Nathanael S, Jänne, Pasi A

“…Epidermal growth factor receptor (EGFR) therapy using small-molecule tyrosine kinase inhibitors (TKIs) is initially efficacious in patients with EGFR-mutant…”
Get full text

Genomic and pathological heterogeneity in clinically diagnosed small cell lung cancer in never/light smokers identifies therapeutically targetable alterations by Ogino, Atsuko, Choi, Jihyun, Lin, Mika, Wilkens, Margaret K., Calles, Antonio, Xu, Man, Adeni, Anika E., Chambers, Emily S., Capelletti, Marzia, Butaney, Mohit, Gray, Nathanael S., Gokhale, Prafulla C., Palakurthi, Sangeetha, Kirschmeier, Paul, Oxnard, Geoffrey R., Sholl, Lynette M., Jänne, Pasi A.

“…Small‐cell lung cancer (SCLC) occurs infrequently in never/former light smokers. We sought to study this rare clinical subset through next‐generation…”
Get full text

Effects of Vandetanib on Lung Adenocarcinoma Cells Harboring Epidermal Growth Factor Receptor T790M Mutation In vivo by ICHIHARA, Eiki, OHASHI, Kadoaki, TAKIGAWA, Nagio, OSAWA, Masahiro, OGINO, Atsuko, TANIMOTO, Mitsune, KIURA, Katsuyuki

“…Vandetanib is a novel multitarget tyrosine kinase inhibitor (TKI) that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), with additional…”
Get full text

The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor by Kobayashi, Naruyuki, Toyooka, Shinichi, Soh, Junichi, Yamamoto, Hiromasa, Dote, Hideaki, Kawasaki, Kensuke, Otani, Hiroki, Kubo, Takafumi, Jida, Masaru, Ueno, Tsuyoshi, Ando, Midori, Ogino, Atsuko, Kiura, Katsuyuki, Miyoshi, Shinichiro

“…Abstract Acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), gefitinib and erlotinib, is frequently observed after…”
Get full text

Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib‐resistance in cells carrying EGFR mutation by Uchida, Akiko, Hirano, Seiki, Kitao, Hiroyuki, Ogino, Atsuko, Rai, Kanmei, Toyooka, Shinichi, Takigawa, Nagio, Tabata, Masahiro, Takata, Minoru, Kiura, Katsuyuki, Tanimoto, Mitsune

“…Patients with pulmonary adenocarcinoma carrying the epidermal growth factor receptor (EGFR) mutation tend to display dramatic clinical response to treatment…”
Get full text

Ovarian abscess caused by Helicobacter cinaedi in a patient with endometriosis by Sato, Hiroshi, Ogino, Atsuko, Matsuzaka, Sunao, Asami, Yuna, Kanbayashi, Shota, Masuda, Miho, Nakashima, Ayaka, Yasuda, Miki, Morishita, Hajime, Ando, Yukiko, Oida, Kenji, Taguchi, Nao, Hirose, Masaya

“…Helicobacter cinaedi is a rarely encountered pathogen that easily induces bacteremia. Various foci of H. cinaedi infection have been reported; however, no case…”
Get full text

Immunohistochemical detection of neuroendocrine differentiation in non-small-cell lung cancer and its clinical implications by Segawa, Yoshihiko, Takata, Saburo, Fujii, Masanori, Oze, Isao, Fujiwara, Yoshiro, Kato, Yuka, Ogino, Atsuko, Komori, Eisaku, Sawada, Shigeki, Yamashita, Motohiro, Nishimura, Rieko, Teramoto, Norihiro, Takashima, Shigemitsu

“…Purpose The purpose of this study was to prospectively assess the clinical implications of neuroendocrine (NE) differentiation in non-small-cell lung cancer…”
Get full text

Intrapleural chemotherapy--current status and problems in Japan by Ogino, Atsuko, Shinkai, Tetsu

“…The efficacy of anti neoplastic agents for chest catheter pleurodesis remains controversial, and little is known regarding the optimal treatment protocol. Of…”
Get more information

Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non―Small Cell Lung Cancer by CARDARELLA, Stephanie, OGINO, Atsuko, NISHINO, Mizuki, BUTANEY, Mohit, SHEN, Jeanne, LYDON, Christine, YEAP, Beow Y, SHOLL, Lynette M, JOHNSON, Bruce E, JÄNNE, Pasi A

“…BRAF mutations are found in a subset of non-small cell lung cancers (NSCLC). We examined the clinical characteristics and treatment outcomes of patients with…”
Get full text

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer by Kitajima, Shunsuke, Tani, Tetsuo, Springer, Benjamin F., Campisi, Marco, Osaki, Tatsuya, Haratani, Koji, Chen, Minyue, Knelson, Erik H., Mahadevan, Navin R., Ritter, Jessica, Yoshida, Ryohei, Köhler, Jens, Ogino, Atsuko, Nozawa, Ryu-Suke, Sundararaman, Shriram K., Thai, Tran C., Homme, Mizuki, Piel, Brandon, Kivlehan, Sophie, Obua, Bonje N., Purcell, Connor, Yajima, Mamiko, Barbie, Thanh U., Lizotte, Patrick H., Jänne, Pasi A., Paweletz, Cloud P., Gokhale, Prafulla C., Barbie, David A.

“…KRAS-LKB1 (KL) mutant lung cancers silence STING owing to intrinsic mitochondrial dysfunction, resulting in T cell exclusion and resistance to programmed cell…”
Get full text

Phase I Study of Irinotecan and Amrubicin in Patients with Advanced Non-Small-Cell Lung Cancer by HOTTA, Katsuyuki, TAKIGAWA, Nagio, NOGAMI, Naoyuki, HARITA, Shingo, OKIMOTO, Niro, UEOKA, Hiroshi, TANIMOTO, Mitsune, KIURA, Katsuyuki, TABATA, Masahiro, UMEMURA, Shigeki, OGINO, Atsuko, UCHIDA, Akiko, BESSHO, Akihiro, SEGAWA, Yoshihiko, SHINKAI, Tetsu

“…Background: Combination chemotherapy of irinotecan and amrubicin for advanced non-small cell lung cancer (NSCLC) has not been fully evaluated. To determine the…”
Get full text

Abstract 3783: Effective MEK inhibitor combinations to target tumor heterogeneity in EGFR mutant transformed SCLC by Ogino, Atsuko, Mu, Xinmeng Jasmine, Lin, Mika, Calles, Antonio, Wang, Stephen, Xu, Man, Scholl, Lynette M., Oxnard, Geoffrey R., Kirschmeier, Paul, Jänne, Pasi A.

“…Abstract Background: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are effective for the treatment of EGFR-mutant non-small lung…”
Get full text

ERK Inhibitor LY3214996-Based Treatment Strategies for RAS -Driven Lung Cancer by Köhler, Jens, Zhao, Yutong, Li, Jiaqi, Gokhale, Prafulla C, Tiv, Hong L, Knott, Aine R, Wilkens, Margaret K, Soroko, Kara M, Lin, Mika, Ambrogio, Chiara, Musteanu, Monica, Ogino, Atsuko, Choi, Jihyun, Bahcall, Magda, Bertram, Arrien A, Chambers, Emily S, Paweletz, Cloud P, Bhagwat, Shripad V, Manro, Jason R, Tiu, Ramon V, Jänne, Pasi A

“…gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB…”
Get full text

Abstract 955: Combined inhibition of MEK and mTOR pathways is effective in NRAS Q61K mutant small cell lung cancer by Ogino, Atsuko, Lin, Mika, Gokhale, Prafulla C., Wilkens, Margaret K., Choi, Jihyun, Calles, Antonio, Xu, Man, Capelletti, Marzia, Oxnard, Geoffrey, Gray, Nathanael S., Kirschmeier, Paul, Jänne, Pasi A.

“…Abstract Background: Small cell lung cancer (SCLC) is a heterogeneous disease, consisting of a phenotypically diverse population of cells, often described as…”
Get full text

Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR -mutant lung cancer by Eser, Pınar Özden, Paranal, Raymond M, Son, Jieun, Ivanova, Elena, Kuang, Yanan, Haikala, Heidi M, To, Ciric, Okoro, Jeffrey J, Dholakia, Kshiti H, Choi, Jihyun, Eum, Yoonji, Ogino, Atsuko, Missios, Pavlos, Ercan, Dalia, Xu, Man, Poitras, Michael J, Wang, Stephen, Ngo, Kenneth, Dills, Michael, Yanagita, Masahiko, Lopez, Timothy, Lin, Mika, Tsai, Jeanelle, Floch, Nicolas, Chambers, Emily S, Heng, Jennifer, Anjum, Rana, Santucci, Alison D, Michael, Kesi, Schuller, Alwin G, Cross, Darren, Smith, Paul D, Oxnard, Geoffrey R, Barbie, David A, Sholl, Lynette M, Bahcall, Magda, Palakurthi, Sangeetha, Gokhale, Prafulla C, Paweletz, Cloud P, Daley, George Q, Jänne, Pasi A

“…The clinical efficacy of epidermal growth factor receptor (EGFR)–targeted therapy in -mutant non–small cell lung cancer is limited by the development of drug…”
Get more information

Abstract 1732: Switch to MET oncogene dependence as a novel mechanism of drug resistance in EGFR- mutant lung cancer by Eser, Pinar Ö., Paranal, Raymond M., Poitras, Michael J., Xu, Man, Wang, Stephen, Ogino, Atsuko, Choi, Jihyun, Missios, Pavlos, Haikala, Heidi M., Son, Jieun, Lin, Mika, Yanagita, Masahiko, Gokhale, Prafulla C., Daley, George Q., Jänne, Pasi A.

“…Abstract Introduction: Non-small cell lung cancers harboring sensitizing gain-of-function mutations in the epidermal growth factor receptor (EGFR) are treated…”
Get full text